Clinical trials · Washington, D.C., DC
Metastatic Breast Cancer clinical trials in Washington, D.C.
We’re tracking 138 recruiting metastatic breast cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT07007559RecruitingPhase 2
Evorpacept with trastuzumab and chemo for HER2-positive breast cancer
This study tests an experimental drug called evorpacept when given with trastuzumab and chemotherapy for people with HER2-positive breast cancer that has spread. The goal is to see if this combination can shrink tumors or slow down the cancer.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04852887RecruitingPhase 3
Testing shorter breast radiation after low-risk hormone breast cancer
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Washington D.C., District of ColumbiaAges 50–70 - NCT06748222RecruitingPhase 3
Online mindfulness program for breast cancer survivors
This trial tests a 6-week online mindfulness program to help breast cancer survivors manage mild to moderate depression. You may qualify if you finished active treatment within the last 5 years and can use a digital device.
Washington D.C., District of ColumbiaAges 18–50 - NCT06065748RecruitingPhase 3
New hormone therapy for advanced breast cancer after prior treatment
This trial tests a new oral hormone therapy, giredestrant, against a standard hormone therapy (fulvestrant) when both are given with a CDK4/6 inhibitor. It is for people with advanced ER-positive, HER2-negative breast cancer that has come back after initial hormone therapy, and who have not yet had other treatments for advanced disease.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06966453RecruitingPhase 1/Phase 2
Study of disitamab vedotin for HER2-positive advanced breast cancer
This study tests a new drug called disitamab vedotin for people with advanced breast cancer that has a certain amount of HER2 protein. Depending on your HER2 and hormone receptor status, you may be eligible for one of three groups, each with different prior treatment requirements.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05467891RecruitingPhase 2
Ribociclib plus hormone therapy for recurrent breast cancer
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Washington D.C., District of ColumbiaAges 12 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Silver Spring, MarylandAges Any age - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Silver Spring, MarylandAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Silver Spring, MarylandAges 18 years+ - NCT06401421Recruiting
Blood test for tumor DNA after breast cancer chemo
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
Silver Spring, MarylandAges 18 years+ - NCT03053193Recruiting
Testing gene activity to guide breast cancer treatment
This study links breast tumor test results from MammaPrint and optional BluePrint (and full genetic data) with real-world clinical information to understand which new gene activity patterns matter. It may help future patients by improving how doctors use these tests to guide care.
Silver Spring, MarylandAges 18 years+ - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Silver Spring, MarylandAges 18 years+ - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Silver Spring, MarylandAges 18–130 - NCT07067138Recruiting
Genetic testing to guide treatment for advanced breast cancer
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
Bethesda, MarylandAges 18–120 - NCT03412877RecruitingPhase 2
Personalized immune-cell therapy for advanced metastatic cancers
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
Bethesda, MarylandAges 18–72 - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT06253494RecruitingPhase 1/Phase 2
Combination therapy trial for advanced endometrial cancer
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
Bethesda, MarylandAges 18–120 - NCT00068003Enrolling by invitation
Harvesting Cancer Cells for Experimental Treatment
This trial collects immune cells from cancer patients or healthy volunteers to develop new experimental cancer treatments. Researchers will take a sample of your tumor or blood cells, grow them in the lab, and study how to use them to fight your cancer.
Bethesda, MarylandAges 18 years+ - NCT01174121RecruitingPhase 2
Immunotherapy made from your tumor-fighting immune cells
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for certain metastatic cancers. It’s designed for people whose cancer has not responded to standard treatments and who can safely provide a small tumor sample for cell-making.
Bethesda, MarylandAges 18–72
Hear when a new Metastatic Breast Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Metastatic Breast Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting metastatic breast cancer studies listed above.
- MedStar Georgetown University Hospital · 6 studies
- MedStar Washington Hospital Center · 6 studies
- National Institutes of Health Clinical Center · 6 studies
- Sinai Hospital of Baltimore · 6 studies
- Greater Baltimore Medical Center · 5 studies
- University of Maryland Baltimore Washington Medical Center · 5 studies
- University of Maryland Greenebaum Comprehensive Cancer Center · 5 studies
- University of Maryland Shore Medical Center · 4 studies
What taking part in a metastatic breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic breast cancer studies in District of Columbia.
Common questions
- Are there metastatic breast cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 138 recruiting metastatic breast cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic breast cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic breast cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.